Curis Announces Key Management Addition
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 1, 2002--Curis, Inc. (NASDAQ: CRIS - News) announced that Christopher U. Missling, PhD, has accepted the position of Senior Vice President of Finance and Chief Financial Officer. Dr. Missling is an important addition to the Curis executive management team and brings more than ten years of strategic financial experience in the biotechnology and pharmaceutical fields. Dr. Missling was most recently Chief Financial Officer at Axaron Bioscience AG, a genomics biotechnology company. Prior to that he was Head of Financial Planning at Aventis, SA, a leading pharmaceutical company, where he was responsible for financial modeling and determining investment valuations. His experience also includes investment banking at Deutsche Bank and corporate finance at Aventis SA and Hoechst AG. Dr. Missling received his MBA from the Kellogg Graduate School of Management, with a focus on partnership valuations in the biotechnology and pharmaceutical industries, and his PhD and MSc from Ludwig-Maximilians-University in Munich.
"Dr. Missling's experience in both the financial and operations management of public companies and financial modeling in the biopharmaceutical industry will make him an extremely important addition to the Curis executive team," said Daniel R. Passeri, President and Chief Executive Officer. "As Curis evolves, his experience will prove invaluable to accelerate our budgetary discipline initiatives to the next level of development and provide us with the financial modeling to enhance shareholder value. Dr. Missling possesses the ideal background to oversee the financial operations, model Curis' business opportunities, and augment the management team with solid financial and strategic thinking expertise."
About Curis, Inc.
Curis, Inc. is generating therapies that regulate the pathways used by the body to maintain and restore health. The company focuses on signaling pathways that govern the proliferation and differentiation of cells. These same pathways control maintenance, repair, and regeneration of tissues and organs from infancy through old age. This approach has created an approved product for bone regeneration and enables Curis to build a portfolio of product candidates in neurology, kidney disease, and cancer. For more information, please visit the Curis web site at www.curis.com.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements address a variety of subjects, including, for example, cost savings, cash burn rate, operating capital requirements, operating efficiencies, strategic collaboration efforts and product development efforts. Statements in this press release that state Curis' or management's intentions, plans, expectations or predictions of future events are forward-looking statements. The matters discussed in this press release also involve risks and uncertainties that may cause Curis' actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: Curis' need for partnerships to move forward its cell therapy programs, the early stage of product development of Curis' retained programs, uncertainties related to clinical trials, uncertainties related to Curis' ability to raise additional capital, changes in or an inability to execute Curis' realigned business strategy and other risk factors described from time to time in Curis' periodic reports and registration statements filed with the Securities and Exchange Commission, including, without limitation, Curis' Annual Report on Form 10-K for the year ended December 31, 2000 filed on March 30, 2001 and the Company's Post Effective Amendment No. 1 on Form S-3 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on August 10, 2001. Curis cannot guarantee any future results, levels of activity, performance, or achievements. Moreover, neither Curis nor anyone else assumes responsibility for the accuracy and completeness of any forward-looking statements. Curis undertakes no obligation to update any of the forward-looking statements after the date of this press release.
--------------------------------------------------------------------------------
Contact:
Curis, Inc.
Henry W. McCusker, (617) 503-6641
or
Noonan Russo Presence
Melissa Wainberg, (212) 845-4262 |
